ReviewJournal of cancer research and clinical oncology2026
Real-world data on oncology in Morocco: a narrative review of four decades of national evidence.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeReal-world data (RWD) has become essential to guide oncology practice and policy. However, in Morocco, the extent and quality of available oncology RWD remain unclear. This study aims to address this gap by examining the current status of RWD in oncology in the Moroccan context.
methodsWe systematically identified and synthesized 308 Moroccan cancer studies (1985-2025) drawn from different electronic databases. Eligible studies included those based on population registries, as well as retrospective and prospective clinical cohorts, molecular and genetic studies, and psycho-oncological or health-system analyses. Data were extracted across five domains: (1) epidemiology, (2) molecular biology, (3) treatment outcomes, (4) survivorship and quality of life, and (5) system-level and public health interventions.
resultsBreast (25%), colorectal (12%), and lung cancers (10%) were the most frequently studied. Most RWD outputs originated from Casablanca (34%), followed by Rabat (27%) and Fez (18%). Clinical and epidemiological studies (56%) were the most predominant study types while molecular papers (21%) highlighted actionable biomarkers: EGFR, KRAS, TP53, BRCA1/2, and VEGF.56
conclusionMorocco has transitioned from case-series oncology research to integrated molecular-epidemiologic RWD networks. Strengthening national data interoperability, biobank integration, and linkage between registries and clinical outcomes is now imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.